Amneal launches 4 new generic products, including vasopressin single-dose

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced that it has received abbreviated new drug application (anda) approval from the u.s. food and drug administration (“fda”) for four generics products, including vasopressin injection 1ml (single-dose). the four recently approved products include:   product dosage category u.s. ttm iqvia sales (june 2022) 1 vasopressin injection 1ml injectable $624 million 2 famotidine for oral
AMRX Ratings Summary
AMRX Quant Ranking